Geron mit Hammernews!! (Seite 289)
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 21.03.24 13:47:21 von
neuester Beitrag 21.03.24 13:47:21 von
Beiträge: 3.090
ID: 709.348
ID: 709.348
Aufrufe heute: 0
Gesamt: 213.067
Gesamt: 213.067
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GERN
3,7900
USD
+6,46 %
+0,2300 USD
Letzter Kurs 26.04.24 Nasdaq
Neuigkeiten
25.04.24 · Business Wire (engl.)  |
18.04.24 · Business Wire (engl.) |
03.04.24 · Business Wire (engl.) |
19.03.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 7,5200 | +47,16 | |
| 0,5922 | +44,44 | |
| 0,7000 | +36,69 | |
| 4,7450 | +35,57 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Sag mal Meislo ....
... hast du eine Ahnung warum Geron so abhebt. Ok ... ist ein Wert mit Zukunftschancen aber über 22 % derzeit ohne irgenwelche News ist schon etwas komisch!
Will mich aber keinesfalls beschweren
... Bärli
... hast du eine Ahnung warum Geron so abhebt. Ok ... ist ein Wert mit Zukunftschancen aber über 22 % derzeit ohne irgenwelche News ist schon etwas komisch!
Will mich aber keinesfalls beschweren
... Bärli
Ist noch nicht durch da sich Deutschland sperrt wenn ich richtig informiert bin aber Geron hat ja in GB ein Labor wo in etwa zwei Jahren klinische Versuche an Rückenmarkverletzungen mit Stammzellen starten sollen
Geron bis jetzt mit 20 % im Plus
EU to Adopt Stem Cell Research Rules This Week
Mon Jul 7, 5:49 PM ET Add Health - Reuters to My Yahoo!
BRUSSELS (Reuters) - The European Commission (news - web sites) will adopt new guidelines this week regulating the use of embryos in EU-funded research in a move aimed at heading off a ban on the controversial technology, an EU spokesman said Monday.
Since the start of the year, no European Union (news - web sites) funds have been given to scientists involved in creating embryos to carry out stem cell research.
"The research moratorium finishes at the end of 2003 and we want to have comprehensive guidelines in place," said European Commission Research spokesman, Fabio Fabbi.
The EU executive is expected to adopt the proposal on Wednesday but it needs the approval of member states and the European Parliament to become law. This is expected for the end of the year, Fabbi said.
Scientists say the research could yield cures for diabetes, Alzheimer`s and Parkinson`s disease (news - web sites). But opponents argue that the new technology will end in designer babies and reproductive cloning.
"The idea is not to encourage the creation of new embryos but the use of ones already existing," Fabbi said.
The current EU research budget is worth 17.5 billion euros but only a few million euros are spent on stem cell research, Fabbi said
Geron bis jetzt mit 20 % im Plus
EU to Adopt Stem Cell Research Rules This Week
Mon Jul 7, 5:49 PM ET Add Health - Reuters to My Yahoo!
BRUSSELS (Reuters) - The European Commission (news - web sites) will adopt new guidelines this week regulating the use of embryos in EU-funded research in a move aimed at heading off a ban on the controversial technology, an EU spokesman said Monday.
Since the start of the year, no European Union (news - web sites) funds have been given to scientists involved in creating embryos to carry out stem cell research.
"The research moratorium finishes at the end of 2003 and we want to have comprehensive guidelines in place," said European Commission Research spokesman, Fabio Fabbi.
The EU executive is expected to adopt the proposal on Wednesday but it needs the approval of member states and the European Parliament to become law. This is expected for the end of the year, Fabbi said.
Scientists say the research could yield cures for diabetes, Alzheimer`s and Parkinson`s disease (news - web sites). But opponents argue that the new technology will end in designer babies and reproductive cloning.
"The idea is not to encourage the creation of new embryos but the use of ones already existing," Fabbi said.
The current EU research budget is worth 17.5 billion euros but only a few million euros are spent on stem cell research, Fabbi said
Im Amiland schon bei 8,54
gruss meislo
gruss meislo
Ok ... OK ....
sieht so aus als ob wir (ich!) heute für die Verschnaufpause entschädigt werde. Will ja den Tag nicht vor dem Abend loben aber ... nur weiter so!
:-)
sieht so aus als ob wir (ich!) heute für die Verschnaufpause entschädigt werde. Will ja den Tag nicht vor dem Abend loben aber ... nur weiter so!
:-)
Hallo Meislo!
Mensch, wollte eigentlich jetzt bald mal so die Überlegung kundtun, ob man in diese Seitwärtsbewegung viellicht sogar aufstocken sollte, oder ob sich die Aktie noch einmal Richtung vier US-Dollar bewegt. Tja, und jetzt das.
Wollte mich auch noch für deine prompte Antwort bezüglich Poet bedanken. Vielleicht komme ich auf dein Angebot mal zurück. Danke!
Gruß, greenhorn
Mensch, wollte eigentlich jetzt bald mal so die Überlegung kundtun, ob man in diese Seitwärtsbewegung viellicht sogar aufstocken sollte, oder ob sich die Aktie noch einmal Richtung vier US-Dollar bewegt. Tja, und jetzt das.
Wollte mich auch noch für deine prompte Antwort bezüglich Poet bedanken. Vielleicht komme ich auf dein Angebot mal zurück. Danke!
Gruß, greenhorn
Trading Spotlight
ES GEHT WIEDER LOSSSSSSS!!!!!!!!! 8,24 DOLLARRRRRRR bei guten Umsätzen
from Briefing dot com:
Live Headline
08-Jul-03
11:44 ET Geron Corp nearing valuation inflection point -- Rodman & Renshaw (GERN) 7.97 +0.79: Rodman & Renshaw believes that GERN shares are positioned to appreciate in the near-term as biotechnology investors become aware of the preclinical data from the co`s oncology and regenerative medicine programs. Notes that preclinical results of the co`s telomerase inhibitor, GRN163, will be presented at the upcoming AACR meeting on July 14. While the majority of products are early in development, firm believes GERN is nearing a significant valuation inflection point. Believes GERN could exceed its $9 target as a result of near-term news flow and the potential for a partnering agreement with big Pharma/biotechnology companies
gruss meislo
from Briefing dot com:
Live Headline
08-Jul-03
11:44 ET Geron Corp nearing valuation inflection point -- Rodman & Renshaw (GERN) 7.97 +0.79: Rodman & Renshaw believes that GERN shares are positioned to appreciate in the near-term as biotechnology investors become aware of the preclinical data from the co`s oncology and regenerative medicine programs. Notes that preclinical results of the co`s telomerase inhibitor, GRN163, will be presented at the upcoming AACR meeting on July 14. While the majority of products are early in development, firm believes GERN is nearing a significant valuation inflection point. Believes GERN could exceed its $9 target as a result of near-term news flow and the potential for a partnering agreement with big Pharma/biotechnology companies
gruss meislo
Nun, andere Biotechwerte sind kräftig eingebrochen dagegen hält Geron sich ja gerade noch gut.
gruss meislo
gruss meislo
Irgendwie finde ich es etwas beunruhigend daß Geron den Anstieg der letzten 2 Wochen praktisch verschlafen hat. Ging zwar vorher schön aufwärts aber .... Hmmmmm ?
Gutes oder Schlechtes Zeichen?
Grüße vom Bärli
Gutes oder Schlechtes Zeichen?
Grüße vom Bärli
AACR-MEETING
Hier das Programm von Geron wobei der Montag der spannende Teil beinhaltet da Geron ein IND für GNR 163-Inhinitor für dieses Jahr geplant hat. Vielleicht werden ja in dieser Hinsicht News veröffentlicht!! Vom Samstagstermin verspreche ich mir weniger da diese Daten schon im April vorab veröffentlicht wurden
Monday
12:00 PM -
4:00 PM R4615 - Preclinical safety and stability profile of GRN163, a highly potent and specific telomerase inhibitor
David B. Karpf, Max B. Yonker, James Trager, Ellen Wunder, Denise Nazzal, Allison C. Chin. Geron Corp., Menlo Park, CA.
Drug Mechanisms and Cell Death Responses
Poster Sessions
Washington Convention Center, Hall B-C
AACR July 11-14 Washington, DC
www.aacr.org/2003AM/2003AM.asp
Saturday
9:40 AM -
9:55 AM 2976 - Vaccination of patients with hormone-refractory prostate cancer using telomerase RNA transfected DC: Results from a Phase I clinical trial
Zhen Su, Philipp Dahm, Jens Dannull, Christian deBeck, Alfonso Crisci, Doris Coleman, Donna Yancey, John Higgins, Donna Niedzwiecki, Eli Gilboa, Johannes W. Vieweg. Duke University Medical Center, Durham, NC.
Novel Vaccine Strategies
Minisymposia
Washington Convention Center, Room 207
Und hier ein paar Informationen zu GNR 163
aacr03.agora.com/planner/displayabstract.asp?presentationid=…
Abstract Number: R4615
Preclinical safety and stability profile of GRN163, a highly potent and specific telomerase inhibitor
David B. Karpf, Max B. Yonker, James Trager, Ellen Wunder, Denise Nazzal, Allison C. Chin. Geron Corp., Menlo Park, CA.
Telomerase is expressed by virtually all aggressive cancers, where its activity is required for the continued proliferation and lethal behavior of cancer cells. However, telomerase is not expressed by most normal tissues. It therefore represents an attractive molecular target for cancer therapy. GRN163 is a 13-mer thio-phosphoramidate oligonucleotide that is targeted to the template region of hTR, where it binds with high affinity and inhibits telomerase activity with low pM IC50 in biochemical assays, and low- to sub ìM IC50 in multiple different cancer cells tested without uptake enhancers. In in vivo studies in athymic mice and rats, GRN163 has demonstrated substantial efficacy against myeloma, lymphoma, malignant glioma, prostate cancer, and cervical cancer tumors following intra-tumoral, intracranial (IC), intraperitoneal (IP) or intravenous (IV) administration. In all of these studies the treatment has been very well tolerated, with no signs of toxicity or weight loss in parenteral dosing studies with doses as high as 20 mg/kg/d x 8 weeks (IP) or 10 mg/kg/d x 10 weeks (IV), or in IC infusion studies with doses up to 2.2 mg over 7-14 days. Two single ascending dose acute toxicity studies in mice demonstrated excellent tolerability up to doses of 1000 mg/kg. A 4-week GLP toxicity study revealed no toxicity in rats treated with IV doses as high as 10.5 mg/kg/d or IC doses as high as 0.105 mg/d. A 7-day GLP toxicity study in dogs has completed the in-life phase, and demonstrated excellent tolerability of IV doses as high as 12 mg/kg/d and IC doses up to 3.43 mg/d, with no signs of the immunostimulation or thrombocytopenia typically seen with bolus injections of phosphorothioate oligos. Labs and histopathology results from these studies will be presented at the meeting. Additionally, Geron has completed several studies to assess the stability of GRN163 in freeze-dried and liquid formulations, with the objective of challenging the stability of potential GRN163 drug product formulations under target and accelerated conditions. A 24-week accelerated stability study of GRN163 formulated in PBS has so far demonstrated good physical, chemical and biochemical stability following storage at 2-8° C up to 18 weeks, and at 37° C up to 6 weeks. In summary, GRN163 represents a highly potent and specific telomerase inhibitor with demonstrated anti-tumor efficacy in several preclinical models of cancer. Its high specificity for telomerase predicts that it should avoid the toxicities associated with most current cancer therapies. To date, GRN163 demonstrates appropriate stability in both liquid and freeze-dried formulations, and the preclinical safety data support the prediction that GRN163 may represent an effective and well-tolerated cancer treatment.
Presenter: David B. Karpf
Affiliation: Geron Corp., Menlo Park, CA . Email: dkarpf@geron.com
Copyright © 2003 American Association for Cancer Research. All rights reserved.
Citation for abstracts scheduled for publication: Proceedings of the AACR, Volume 44, 2nd ed., July 2003.
Citation for abstracts not scheduled for publication: Proceedings of the AACR, Volume 44, 1st ed., March 2003.
Könnte spannend werden
gruss meislo
Hier das Programm von Geron wobei der Montag der spannende Teil beinhaltet da Geron ein IND für GNR 163-Inhinitor für dieses Jahr geplant hat. Vielleicht werden ja in dieser Hinsicht News veröffentlicht!! Vom Samstagstermin verspreche ich mir weniger da diese Daten schon im April vorab veröffentlicht wurden
Monday
12:00 PM -
4:00 PM R4615 - Preclinical safety and stability profile of GRN163, a highly potent and specific telomerase inhibitor
David B. Karpf, Max B. Yonker, James Trager, Ellen Wunder, Denise Nazzal, Allison C. Chin. Geron Corp., Menlo Park, CA.
Drug Mechanisms and Cell Death Responses
Poster Sessions
Washington Convention Center, Hall B-C
AACR July 11-14 Washington, DC
www.aacr.org/2003AM/2003AM.asp
Saturday
9:40 AM -
9:55 AM 2976 - Vaccination of patients with hormone-refractory prostate cancer using telomerase RNA transfected DC: Results from a Phase I clinical trial
Zhen Su, Philipp Dahm, Jens Dannull, Christian deBeck, Alfonso Crisci, Doris Coleman, Donna Yancey, John Higgins, Donna Niedzwiecki, Eli Gilboa, Johannes W. Vieweg. Duke University Medical Center, Durham, NC.
Novel Vaccine Strategies
Minisymposia
Washington Convention Center, Room 207
Und hier ein paar Informationen zu GNR 163
aacr03.agora.com/planner/displayabstract.asp?presentationid=…
Abstract Number: R4615
Preclinical safety and stability profile of GRN163, a highly potent and specific telomerase inhibitor
David B. Karpf, Max B. Yonker, James Trager, Ellen Wunder, Denise Nazzal, Allison C. Chin. Geron Corp., Menlo Park, CA.
Telomerase is expressed by virtually all aggressive cancers, where its activity is required for the continued proliferation and lethal behavior of cancer cells. However, telomerase is not expressed by most normal tissues. It therefore represents an attractive molecular target for cancer therapy. GRN163 is a 13-mer thio-phosphoramidate oligonucleotide that is targeted to the template region of hTR, where it binds with high affinity and inhibits telomerase activity with low pM IC50 in biochemical assays, and low- to sub ìM IC50 in multiple different cancer cells tested without uptake enhancers. In in vivo studies in athymic mice and rats, GRN163 has demonstrated substantial efficacy against myeloma, lymphoma, malignant glioma, prostate cancer, and cervical cancer tumors following intra-tumoral, intracranial (IC), intraperitoneal (IP) or intravenous (IV) administration. In all of these studies the treatment has been very well tolerated, with no signs of toxicity or weight loss in parenteral dosing studies with doses as high as 20 mg/kg/d x 8 weeks (IP) or 10 mg/kg/d x 10 weeks (IV), or in IC infusion studies with doses up to 2.2 mg over 7-14 days. Two single ascending dose acute toxicity studies in mice demonstrated excellent tolerability up to doses of 1000 mg/kg. A 4-week GLP toxicity study revealed no toxicity in rats treated with IV doses as high as 10.5 mg/kg/d or IC doses as high as 0.105 mg/d. A 7-day GLP toxicity study in dogs has completed the in-life phase, and demonstrated excellent tolerability of IV doses as high as 12 mg/kg/d and IC doses up to 3.43 mg/d, with no signs of the immunostimulation or thrombocytopenia typically seen with bolus injections of phosphorothioate oligos. Labs and histopathology results from these studies will be presented at the meeting. Additionally, Geron has completed several studies to assess the stability of GRN163 in freeze-dried and liquid formulations, with the objective of challenging the stability of potential GRN163 drug product formulations under target and accelerated conditions. A 24-week accelerated stability study of GRN163 formulated in PBS has so far demonstrated good physical, chemical and biochemical stability following storage at 2-8° C up to 18 weeks, and at 37° C up to 6 weeks. In summary, GRN163 represents a highly potent and specific telomerase inhibitor with demonstrated anti-tumor efficacy in several preclinical models of cancer. Its high specificity for telomerase predicts that it should avoid the toxicities associated with most current cancer therapies. To date, GRN163 demonstrates appropriate stability in both liquid and freeze-dried formulations, and the preclinical safety data support the prediction that GRN163 may represent an effective and well-tolerated cancer treatment.
Presenter: David B. Karpf
Affiliation: Geron Corp., Menlo Park, CA . Email: dkarpf@geron.com
Copyright © 2003 American Association for Cancer Research. All rights reserved.
Citation for abstracts scheduled for publication: Proceedings of the AACR, Volume 44, 2nd ed., July 2003.
Citation for abstracts not scheduled for publication: Proceedings of the AACR, Volume 44, 1st ed., March 2003.
Könnte spannend werden
gruss meislo
Immer diese flachen Seitwaertsbewegungen, hab ich so noch nicht gesehen bei einer volatilen viel gehandelten Aktie.
Sieht aber ganz gut aus.
Sieht aber ganz gut aus.
Durchsuchen
